I agree, RXMD is essentially debt free and sitting on millions in new capital; with the share dilution cost fully known and held by the new investors. It is a best case scenario for RXMD, with new partners and new majority shareholders that have proven wherewithal to deliver RXMD's vision.
$0.2 minimum, and $1 on the table with the right news, IMO.